Work

Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5381

Authors: Umberto Vitolo, Lalita Norasetthada, Jae-Cheol Jo, Biyi Shen, Dina Flink, Min Zhu, Soujanya Chandrasekharan, Jingxiao Chen, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Sabela Bobillo-Varela, Catherine Thieblemont

Institutions: Candiolo Cancer Institute, Chiang Mai University, Ulsan University Hospital, Regeneron (United States), Université Paris Cité, Assistance Publique – Hôpitaux de Paris

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417012996

Cites:

Cited by: 2

Related to: